NAPA, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Senetek PLC , www.senetekplc.com, a life sciences product development company targeting the science of aging to include skincare and dermatological therapeutics, erectile dysfunction, nutrition and cancer, announced today that the Company's marketing partner for Europe has launched Invicorp(R) in Denmark. Invicorp(R) is the Company's proprietary treatment for erectile dysfunction. It is estimated that 52% of men over the age of 40 suffer at some time from erectile dysfunction (ED) and many of them are unsuitable for treatment with existing oral therapies. Invicorp(R), a local injectable treatment, is expected to treat those patients who need drug therapy for ED but are contraindicated for oral phosphodiesterase (PDE) inhibitors such as Viagra(R), Levitra(R) and Cialis(R). "Thirty percent of males afflicted with ED do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable rigidity compared to oral drugs.(1)"
"The launch of Invicorp in Denmark is a major achievement and validates another successful step in the execution of the Company's business plan which targets the commercialization of one new product per year," stated Frank Massino, Senetek Chairman and Chief Executive Officer. "We look forward to Invicorp's success in Denmark and to commercialization in other EU nations beginning in 2007."
About Senetek:
Senetek is a life sciences product development company with an extensive array of intellectual properties covering in excess of 2000 patented and patent applied for compounds and uses targeting the science of aging to include skincare and dermatological therapeutics, erectile dysfunction, nutrition and cancer through RNA interference technology.
The Company's lead commercial product, Kinetin, is currently licensed and marketed by 14 pharmaceutical and cosmeceutical companies such as Valeant Pharmaceuticals and The Body Shop. In addition, the Company has entered into commercial arrangements for its proprietary anti-aging skincare compound, Zeatin, its patented combination drug treatment for erectile dysfunction, Invicorp(R), its novel drug delivery system, Reliaject(R) as well as its proprietary diagnostic monoclonal antibodies.
For additional information, please visit Senetek PLC's Web site at http://www.senetekplc.com.
Safe Harbor Statement:
This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act, including those indicating the financial outlook for fiscal 2006 and those that might imply commercial potential and successful evaluation and development of new compounds. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K/A for the year 2005. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward- looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
KCSA Contacts: Todd Fromer / Garth Russell 212-896-1215 / 1250 tfromer@kcsa.com / grussell@kcsa.com (1) Harmut Porst, MD, International Journal of Impotence Research, September 27, 2000
Senetek PLCCONTACT: Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, or Garth Russell,212-896-1250, grussell@kcsa.com, both of KCSA, for Senetek PLC
Web site: http://www.senetekplc.com/
